Objective To assess the effectivess and safety of Shenkang capsule in the treatment of chronic glomerulonephritis （Qiyinliangxu Syndrome）. Methods A double blind, double dummy and randomized controlled method was adopted. A total of 96 patients were randomized to the treatment group （Shenkang capsule, 2 capsules, twice a day） and the control group （Shenyankang capsule, 2 capsules, twice a day）. The therapeutic course for both groups was 2 months. Results All the results were analyzed on the basis of retention-to-treat（ITT） and per-protocol-population （PP）. For effect of chronic glomerulonephritis in the treatment group, the clinical control rates were 12.86% （9/70） with ITT analysis and 14. 75% （9/61） with PP analysis; the good improvement rates were 12. 86% （9/70） with ITT analysis and 14. 75% （9/61） with PP analysis; the total effective rates were 48. 58% （34/70） and 55.73% （34/61）. In the control group, the clinical control rates were 4. 17% （1/24） with ITT analysis and 5.00% （1/20） with PP analysis respectively; the good improvement rates were 4. 17% （1/24） with ITT analysis and 5.00% （1/20） with PP analysis respectively; the total effective rates were 45. 83% （11/24） with ITT analysis and 55.00% （11/20） with PP analysis. There was no statistical difference between the two groups （P〉0.05）. For Qiyinliangxu syndrome improvement, in the treatment group, the clinical control rate and good improvement rate were 18. 57% （13/70） with ITT analysis and 21.31% （13/61） with PP analysis respectively; the total effective rates were 81.43% （57/70） with ITT analysis and 93. 44% （57/61） with PP analysis respectively; In the control group, the clinical control rate and good improvement rate were 20. 84% （ 5/24 ） with ITT analysis and 25.00% （5/20 ） with PP analysis respectively; the total effective rates were 75. 00% （18/24） with ITT analysis and 85. 00% （17/20） with PP analysis respectively. The results showed no statistical difference between the two groups （P 〉0. 05）. No adverse effects were found. Conclusions No statistical difference was detected between Shengkang capsule and Shenyan capsule groups. No obvious toxic adverse effects were found.
目的 探讨抗核抗体（ANA）在IgA肾病中的阳性率及其对临床的意义。 方法 回顾性分析2007年1月－2009年12月间进行ANA检测的115例IgA肾病患者及59例非IgA肾病慢性肾炎患者的临床资料。统计分析ANA阳性与阴性的临床指标。 结果 IgA肾病患者中有12例（10.4%）存在ANA阳性，与非IgA肾病慢性肾炎中的阳性率比较差异无统计学意义（P＞0.05），ANA阳性的IgA肾病血浆IgG水平较高，病理改变较轻。 结论 IgA肾病ANA阳性的机体免疫有增强，肾功、尿蛋白及病理损害较轻，其对IgA肾病预后的影响仍需进一步研究。